Research programme: MRSA vaccine therapeutics - Bavarian Nordic/ Evaxion Biotech/Technical University of Denmark

Drug Profile

Research programme: MRSA vaccine therapeutics - Bavarian Nordic/ Evaxion Biotech/Technical University of Denmark

Alternative Names: Methicillin-resistant Staphylococcus aureus vaccines - Bavarian Nordic/Evaxion Biotech/Technical University of Denmark; MVA-BN based MRSA vaccines - Bavarian Nordic/Evaxion Biotech/Technical University of Denmark

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Bavarian Nordic; Technical university of denmark
  • Developer Bavarian Nordic; Evaxion Biotech
  • Class Vaccines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 04 Feb 2016 Early research in Methicillin-resistant Staphylococcus aureus infections in Denmark (unspecified route)
  • 04 Feb 2016 Bavarian Nordic, Evaxion Biotech and the Technical University of Denmark agree to co-develop vaccine in Denmark for Methicillin-resistant Staphylococcus aureus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top